BioCorteX
Drug Discovery · Biotechnology
Facts
as of Nov 20, 2026BioCorteX runs in-silico bridge trials that map how the microbiome changes a drug.
- Employees
- 11-50estimated range
- Website
- biocortex.com
These are the key facts about BioCorteX on Alion as of Nov 20, 2026. The latest round is Venture - Series Unknown of $5M, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →BioCorteX has $5M paid in by investors, lenders and donors.
$5MPaid in
Money innewest first
$5MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →Sources name Sofinnova Partners, Hoxton Ventures among the owners or investors of BioCorteX.
Named investors, no share stated2
Holders and shares as each register or filing states them.
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Mar 27, 2023
Each milestone is dated by its source: registers, filings, the press
